Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (10)

« Back to Publications

Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.

Silva de Castro I. et al, (2021), iScience, 24

The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin α4β7 and promotes cellular activation and infection.

Goes LR. et al, (2020), Proc Natl Acad Sci U S A, 117, 32566 - 32573

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.

Schifanella L. et al, (2020), PLoS Pathog, 16

Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.

Gorini G. et al, (2020), PLoS Pathog, 16

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.

Schifanella L. et al, (2019), PLoS Pathog, 15

Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7.

Lertjuthaporn S. et al, (2018), PLoS Pathog, 14

HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition.

Vaccari M. et al, (2018), Nat Med, 24, 847 - 856

The sudden death of Alaric I (c. 370-410AD), the vanquisher of Rome: A tale of malaria and lacking immunity.

Galassi FM. et al, (2016), Eur J Intern Med, 31, 84 - 87

Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120.

Blackburn MJ. et al, (2015), J Immunol, 195, 3227 - 3236

Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections.

Sautto G. et al, (2013), Biomed Res Int, 2013